Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 3—March 2015
Research

Mycoplasma pneumoniae and Chlamydia spp. Infection in Community-Acquired Pneumonia, Germany, 2011–2012

Roger Dumke, Christiane Schnee, Mathias W. Pletz, Jan Rupp, Enno Jacobs, Konrad Sachse1, Gernot Rohde1Comments to Author , and CAPNETZ Study Group2
Author affiliations: Technical University Dresden Institute of Medical Microbiology and Hygiene, Dresden, Germany (R. Dumke, E. Jacobs); Friedrich-Loeffler-Institut, Jena, Germany (C. Schnee, K. Sachse); Jena University Hospital Center for Infectious Diseases and Infection Control, Jena (M.W. Pletz); CAPNETZ STIFTUNG, Hannover, Germany (M.W. Pletz, J. Rupp, G. Rohde); University of Lübeck, Lübeck, Germany (J. Rupp); Maastricht University Medical Centre, Maastricht, the Netherlands (G. Rohde)

Main Article

Table 1

Demographic and clinical characteristics of patients with community-acquired pneumonia whose respiratory tract samples were tested for Mycoplasma pneumoniae, Germany, 2011–2012*

Characteristic All, n = 783 M. pneumoniae–positive, n = 96 M. pneumoniae–negative, n = 687 p value†
Median age, y (range) 61 (18–102) 39.5 (18–84) 64 (18–102) <0.001
Male sex 56.8 43.8 58.7 0.008
BMI (range)
 25.6 (13.9–56.5)
 24.2 (18.8–44.5)
 25.8 (13.9–56.5)
Co-occurring conditions
Chronic pulmonary disease 19.2 6.2 23.1 <0.001
Chronic renal disease 19.2 0 20.6 0.004
Chronic heart failure 26.1 11.3 27.2
Diabetes mellitus 24.9 11.1 25.9
Cerebro-vascular disease
 9.5
 3.7
 9.3
CURB scores‡ <0.001
0 57.3 77.0 54.7
1 31.0 21.8 32.2
2 10.5 1.1 11.8
3 1.2 0 1.4
4
 0
 0
 0
Antimicrobial drug pretreatment 29.3 51.0 26.2 <0.001
Macrolides
 8.0
 7.3
 8.3
 §
Mortality rate
28 d 1.8 0 2.0
180 d 4.6 0 5.2

*Values are percentages except as indicated. BMI, body mass index.
†Only significant values are shown. Comparison between M. pneumoniae-positive and -negative patients by χ2 or Mann-Whitney U test as appropriate.
‡Clinical evaluation of the following risk factors (each scores 1 point): Confusion; blood Urea >7 mmol/L; Respiratory rate ≥30 bpm; Blood pressure <90 (systolic) or ≤60 mm Hg (diastolic).
§Also no significant differences for any other antimicrobial drug classes.

Main Article

1Joint senior authors.

2Members of the CAPNETZ Study Group are listed at the end of this article.

Page created: February 18, 2015
Page updated: February 18, 2015
Page reviewed: February 18, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external